Back to the be­gin­ning: Pfiz­er seeds dis­cov­ery-stage neu­ro start­up Mag­no­lia (af­ter ax­ing its own brain R&D)

Af­ter yank­ing its own neu­ro­science ef­forts —  and re­treat­ing from the fail­ure-strewn bat­tle­ground of brain sci­ence — Pfiz­er is ped­al­ing back to the be­gin­ning in this field. The phar­ma gi­ant is fund­ing a brand-new MD An­der­son spin­out that’s ques­tion­ing the very ba­sics of neu­rode­gen­er­a­tion.

The start­up, called Mag­no­lia Neu­ro­sciences (“Mag­no­lia” as a nod to its Texas roots), is be­ing rather tightlipped about what it’s work­ing on. But CEO Thong Le tells me the com­pa­ny is steer­ing away from tra­di­tion­al ef­forts in the field.

In short, the start­up is tap­ping a body of lit­er­a­ture around a bi­o­log­i­cal process that oc­curs in the womb dur­ing the ear­li­est stages of life. When an em­bryo is form­ing, the body trash­es ex­cess neu­rons in a process called “pro­grammed cell death.” Re­search shows that this same process is re­ac­ti­vat­ed in the brain through­out the course of Alzheimer’s dis­ease, among oth­er neu­ro con­di­tions. Mag­no­lia is hy­poth­e­siz­ing that block­ing spe­cif­ic com­po­nents of this process will pre­serve brain tis­sue in hu­mans and — hope­ful­ly — pre­vent mem­o­ry loss. That’s what they’ve seen in mouse mod­els, any­way.

“Not on­ly can you pre­serve brain tis­sue and en­hance mem­o­ry, but — from a more bi­o­log­i­cal point of view — you could dra­mat­i­cal­ly change the course and de­vel­op­ment of neu­ro­log­i­cal dis­ease,” Le said.

To get to work on the idea, Mag­no­lia has round­ed up $31 mil­lion in a Se­ries A packed with high pro­file cor­po­rate VCs. The stel­lar syn­di­cate was put to­geth­er by Ac­cel­er­a­tor Life Sci­ence Part­ners, a start­up fac­to­ry that churns out these ven­tures by shop­ping aca­d­e­m­ic labs and oth­er hubs of in­no­va­tion around the globe. Once they find some­thing promis­ing, they put to­geth­er a team and spin the tech out in­to a start­up of its own.

It should be not­ed that Le is the CEO at Ac­cel­er­a­tor, which is why he’s head­ing up Mag­no­lia for the time be­ing.

Ac­cel­er­a­tor has satel­lites in New York, Seat­tle, and San Diego, and has launched sev­en star­tups since its in­cep­tion. One of their ven­tures is Lo­do Ther­a­peu­tics, the New York-based com­pa­ny that scored a $969 mil­lion (biobucks) deal with Genen­tech in metage­nomics ear­li­er this year.

Mag­no­lia man­aged to at­tract a slew of cor­po­rate VCs, in­clud­ing the afore­men­tioned Pfiz­er, Eli Lil­ly, Ab­b­Vie Ven­tures, and John­son & John­son In­no­va­tion, among oth­ers. You can see the full list on the com­pa­ny’s press re­lease.

Af­ter scrap­ping its own neu­ro­science work ear­li­er this year, some might see Pfiz­er’s in­vest­ment in star­tups as putting a bandaid over a gap­ing hole. But the phar­ma gi­ant is mak­ing an ef­fort to seed in­no­va­tion out­side of its own labs. In June, the com­pa­ny com­mit­ted an ad­di­tion­al $150 mil­lion to its VC group to in­vest in neu­ro­science star­tups. This in­vest­ment in Mag­no­lia is one of the first bets, it seems.

Le said it ac­tu­al­ly makes a lot of sense for large phar­ma­ceu­ti­cal com­pa­nies to leave the ear­ly dis­cov­ery work to small­er biotechs.

“When it comes to de­vel­op­ing drugs for com­plex dis­eases like Alzheimer’s, to some ex­tent we’re muck­ing with bi­ol­o­gy that we don’t re­al­ly have a per­fect un­der­stand­ing of, which re­quires tak­ing cal­cu­lat­ed risk from a de­vel­op­ment per­spec­tive,” he said. “Large phar­ma com­pa­nies that are pub­licly trad­ed don’t have as much flex­i­bil­i­ty as they’d like to have in terms of be­ing ag­ile and tak­ing the leaps of faith need­ed to push an ear­ly stage pro­gram ag­gres­sive­ly for­ward.”

Le said this lat­est round of fund­ing should move Mag­no­lia to­ward clin­i­cal de­vel­op­ment, al­though he’s not shar­ing time­lines just yet.


Im­age: Ac­cel­er­a­tor and Mag­no­lia CEO Thong Le. Mag­no­lia

Com­mu­ni­cat­ing the val­ue of pre­ci­sion med­i­cine

By Natasha Cowan, Content Marketing Manager at Blue Latitude Health.
Many stakeholders are confused by novel precision medicines, including patients and healthcare professionals. So, how can industry help them to navigate this complexity?

Precision medicine represents a new paradigm in healthcare. It embodies the shift from treating many patients with the same therapy, to having the tools to identify the best treatment for every patient.

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

What differentiates a woman leader in biopharma R&D from a man?

Not much, except there are fewer of them in senior posts. Data suggest women are not more risk-averse, family-oriented or less confident than their male counterparts — indeed the differences between the two sexes are negligible. But a glance at the top R&D positions in Big Pharma leaves little doubt that upward migration in the executive ranks of biopharma R&D is tough.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,300+ biopharma pros reading Endpoints daily — and it's free.

GSK's asth­ma bi­o­log­ic Nu­cala scores in rare blood dis­or­der study

GlaxoSmithKline’s asthma drug Nucala, which received a resounding FDA rejection for use in chronic obstructive pulmonary disease (COPD) last year, has shown promise in a rare blood disorder.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,300+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck buys a fledg­ling neu­rode­gen­er­a­tive biotech spawned by an old GSK dis­cov­ery al­liance. What’s up with that?

Avalon Ventures chief Jay Lichter has a well-known yen for drug development programs picked up in academia. And what he found in Haoxing Xu’s lab at the University of Michigan pricked his interest enough to launch one of his umbrella biotechs in San Diego.
Xu’s work laid the foundation for Avalon to launch Calporta, which has been working on finding small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for lysosomal storage disorders. And that pathway, they believe, points to new approaches on major market neurodegenerative diseases like Parkinson’s, ALS and Alzheimer’s.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,300+ biopharma pros reading Endpoints daily — and it's free.

FDA slaps a hold on an AML tri­al as Mark­er scraps a fail­ing ovar­i­an can­cer pro­gram, sink­ing shares

The FDA has placed a hold on a Phase II AML trial from the small immuno-oncology biotech Marker Therapeutics. Marker disclosed the issue two weeks after responding to FDA concerns, adding it to the Q3 release Tuesday. The company also announced it was scrapping a Phase II ovarian cancer program it determined was unlikely to succeed.

The agency’s concern centers around two reagents used in manufacturing for their trial for acute myeloid leukemia patients who have received a stem cell transplant. The reagents are from third parties and not present in the final product, Marker said.

Eli Lil­ly-backed biotech grabs $100M to dis­patch an­ti­body-oligonu­cleotide con­ju­gates af­ter mus­cu­lar dy­s­tro­phy

Hold up your hand. Make a fist. Now open it. And again.

If you can do it fully and with ease, then the proteins in your hand are likely working properly. If you can’t then they may not be. In people with myotonic muscular dystrophy, something more atomic is going on.

In those folks, the problem is RNA. Certain base pairs repeat far beyond normal, up to 11,000 superfluous letters in some cases. The extended strands form “clumps.” Proteins misform and can’t function properly. They often allow one movement but not the reverse, a condition called myotonia that gives the dystrophy its name.

As­traZeneca sets stage for mar­ket­ing ap­pli­ca­tion with promis­ing piv­otal lu­pus drug da­ta

After fumbling in its first late-stage lupus study, AstraZeneca disclosed that a second pivotal trial testing its experimental drug, anifrolumab, had met the main goal, in August. Earlier this week, the British drugmaker broke out the numbers from its successful study.

Last year, anifrolumab failed to meet the main goal of diminishing disease activity in the 460-patient TULIP I study, a 52-week trial that tested two doses of the drug versus a placebo. But in the 373-patient TULIP II study, the higher dose (300 mg) was compared to patients given a placebo — patients in both arms were on baseline standard care.

FDA Vas­cepa re­view spot­lights new safe­ty sig­nals, pos­si­ble min­er­al oil spoil­er as Amarin hunts a block­buster ap­proval

An in-house FDA review of Amarin’s Vascepa raises a set of hurdles the biotech will have to clear if the biotech expects to get the long-awaited FDA approval that could set it on a path to superstar status. But it appears that Amarin has survived another potential setback without introducing a major new threat to its prospects.

The stakes don’t get much higher, with analysts saying a win this week for Amarin could lead to billions in new sales — provided the agency stamps it with an OK. And investors liked what they say in the FDA review this morning, bumping the stock $AMRN 17%.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,300+ biopharma pros reading Endpoints daily — and it's free.

FDA puts Sol­id Bio’s lead gene ther­a­py pro­gram on hold — again — af­ter an­oth­er pa­tient is hurt by SGT-001

Solid Biosciences continues to be plagued by safety issues.

Close to 18 months after the gene therapy biotech was able to quickly shed an FDA hold on their lead Duchenne muscular dystrophy program for SGT-001, regulators have stepped back in to force another halt after another patient was hit hard by a set of serious adverse events remarkably similar to the first set.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,300+ biopharma pros reading Endpoints daily — and it's free.